Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 5.4% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 59,265 shares of the medical research company’s stock after selling 3,386 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Thermo Fisher Scientific were worth $32,197,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Grayhawk Investment Strategies Inc. acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth $26,000. Advanced Research Investment Solutions LLC increased its stake in shares of Thermo Fisher Scientific by 213.3% during the first quarter. Advanced Research Investment Solutions LLC now owns 47 shares of the medical research company’s stock worth $28,000 after buying an additional 32 shares during the period. Tortoise Investment Management LLC raised its holdings in Thermo Fisher Scientific by 410.0% in the second quarter. Tortoise Investment Management LLC now owns 51 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 41 shares in the last quarter. Better Money Decisions LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $29,000. Finally, Adirondack Trust Co. purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $34,000. Institutional investors and hedge funds own 86.50% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $2.54 during trading hours on Thursday, reaching $547.29. The company had a trading volume of 823,632 shares, compared to its average volume of 1,753,300. The firm has a 50 day simple moving average of $517.90 and a 200-day simple moving average of $541.99. Thermo Fisher Scientific Inc. has a 12-month low of $475.77 and a 12-month high of $672.34. The company has a current ratio of 1.74, a quick ratio of 1.22 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $214.65 billion, a price-to-earnings ratio of 30.76, a PEG ratio of 1.89 and a beta of 0.83.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Thursday, November 10th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 0.22%. The ex-dividend date is Wednesday, December 14th. Thermo Fisher Scientific’s payout ratio is currently 6.75%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 8,200 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, November 3rd. The stock was sold at an average price of $487.45, for a total transaction of $3,997,090.00. Following the completion of the transaction, the chief executive officer now directly owns 178,005 shares in the company, valued at approximately $86,768,537.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Marc N. Casper sold 8,200 shares of the business’s stock in a transaction dated Thursday, November 3rd. The shares were sold at an average price of $487.45, for a total value of $3,997,090.00. Following the completion of the transaction, the chief executive officer now owns 178,005 shares of the company’s stock, valued at approximately $86,768,537.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 8,100 shares of Thermo Fisher Scientific stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $493.16, for a total transaction of $3,994,596.00. Following the sale, the chief executive officer now owns 178,005 shares of the company’s stock, valued at $87,784,945.80. The disclosure for this sale can be found here. Insiders have sold 26,300 shares of company stock valued at $13,091,386 over the last quarter. Corporate insiders own 0.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TMO shares. Morgan Stanley lowered their target price on shares of Thermo Fisher Scientific from $678.00 to $613.00 and set an “overweight” rating for the company in a research note on Thursday, October 27th. StockNews.com began coverage on Thermo Fisher Scientific in a report on Wednesday, October 12th. They issued a “buy” rating on the stock. Benchmark cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Thursday, October 27th. SVB Leerink dropped their price target on shares of Thermo Fisher Scientific from $590.00 to $555.00 and set an “outperform” rating on the stock in a research note on Thursday, October 27th. Finally, Credit Suisse Group lowered their target price on shares of Thermo Fisher Scientific to $620.00 in a report on Thursday, October 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $619.00.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.